Literature DB >> 19232942

Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management.

Michael R Hernandez1, Robert C Shamberger, Christian Seefelder.   

Abstract

Preoperative alpha- and beta-adrenergic receptor block with phenoxybenzamine and labetalol, the intraoperative course of a 4-month-old infant with neuroblastoma and elevated catecholamines causing sweating, hypertension, and tachycardia, are presented. We recommend determination of catecholamine levels and pretreatment with alpha-adrenergic and--if needed--beta-adrenergic receptor antagonists in infants with neuroblastoma and hypertension, tachycardia, or sweating.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232942     DOI: 10.1016/j.jclinane.2008.06.021

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  4 in total

1.  Severe intraoperative hypertension after induction of anesthesia in a child with a neuroblastoma.

Authors:  Hiromi Kako; Thomas Taghon; Giorgio Veneziano; Jennifer H Aldrink; Rose Ayoob; Joseph D Tobias
Journal:  J Anesth       Date:  2013-01-05       Impact factor: 2.078

2.  International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Authors:  Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle
Journal:  Ecancermedicalscience       Date:  2022-02-17

3.  Catecholamines in neuroblastoma: Driver of hypertension, or solely a marker of disease?

Authors:  Matthew Harding; Rebecca J Deyell; Tom Blydt-Hansen
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-06

4.  β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma.

Authors:  E Pasquier; J Street; C Pouchy; M Carre; A J Gifford; J Murray; M D Norris; T Trahair; N Andre; M Kavallaris
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.